ZGNX Stock, Zogenix Inc. Information

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes Fintepla, dose fenfluramine for the treatment of Dravet syndrome, and MT-1621 for a rare, life-threatening mitochondrial depletion disease, thymidine kinase 2 deficiency (TK2d). It operates as a single operating segment engaged in the research, development, and commercialization of pharmaceutical products.